M. S. Nayeem and Rizwan H. Khan Pages 165 - 170 ( 6 )
The application of recombinant immunotoxin and radioimmunoconjugate in Cancer therapy has revived the "magic bullet" concept predicted a century ago. Many of the recombinant antibodies have received FDA approval for various indication of cancer in recent years and numerous others are in clinical trials.
Cancer therapy, recombinant immunotoxins, radioimmunoconjugates, engineered antibody, recombinant antibody
Interdisciplinary BiotechnologyUnit, Aligarh Muslim University, Aligarh-202002, India.